Anika Therapeutics (ANIK) Enterprise Value (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Enterprise Value data on file, last reported at -$66.8 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 11.37% year-over-year to -$66.8 million in Q1 2026; TTM through Mar 2026 was -$66.8 million, a 11.37% increase from a year earlier, with the FY2025 full-year figure at -$81.2 million, down 2.46% from the prior year.
• Enterprise Value for Q1 2026 stood at -$66.8 million, up from -$81.2 million in the prior quarter.
• Over the last five years, Enterprise Value for ANIK reached as high as -$66.8 million in Q1 2026 and fell as low as -$123.6 million in Q2 2022.
• Historically, Enterprise Value has averaged -$96.9 million across 5 years, with a median of -$96.6 million in 2024.
• Across the five-year window, Enterprise Value tumbled 34.04% in 2022 and grew 25.17% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$121.0 million in 2022, then increased by 21.38% to -$95.1 million in 2023, then rose by 16.7% to -$79.2 million in 2024, then decreased by 2.46% to -$81.2 million in 2025, then climbed by 17.72% to -$66.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$66.8 million in Q1 2026, -$81.2 million in Q4 2025, and -$80.2 million in Q3 2025.